New Delhi.- The Indian pharmaceutical company Dr. Reddy’s Laboratories affirmed this Saturday that the regulator of the Asian nation has given the go-ahead to the Russian vaccine clinical trials contra la Covid-19, Sputnik V.
“We have received approval from the Comptroller General of Medicines of India (DCGI) to carry out phase 2 and 3 human trials for the vacuna Sputnik V in India, “the pharmaceutical company and the Russian Direct Investment Fund (FIDR) reported in a joint statement.
Dr. Reddy’s co-director, GV Prasad, said in the statement that this development “will allow clinical trials to begin in India” and fight the pandemic.
The announcement comes after Russia approved in mid-September the supply of 100 million doses of its Covid-19 vaccine to India, which is also being tested in the United Arab Emirates (UAE) and Venezuela.
Read also: Putin Announces Registration of His Second Covid-19 Vaccine; calls it “EpiVacCorona”
Sputnik V was registered on August 11 and is currently in phase III trials, although it has been received with suspicion by the international scientific community due to the speed of the trials and the little information about the drug.
The Asian country, known as the third world pharmacy due to its high production of low-cost generics, is already working on the last ensay phaseor with various vaccines.
Among them is that of AstraZeneca in collaboration with the Serum Institute of India, one of the world’s largest vaccine manufacturers. “Covaxin”, from the Indian laboratory Bharat Biotech International in collaboration with the Indian Council for Medical Research (ICMR), is another candidate.
With 7.4 million cases of coronavirus and 112,998 deaths, India is the second country most affected by the pandemic behind the United States, with 8.2 million infections.